Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to Rilpivirine-based Regimen in HIV-1
NCT03251690Completed
- Sponsor
- Mahidol University
- Start
- Oct 2016
- Primary completion
- Apr 2018
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of rilpivirine in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Mahidol University. Primary endpoint: Sustained Virological Response at 12 months. Started Oct 2016; status: completed.
02
Drugs
rilpivirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03251690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03251690.